Patients with severe asthma who have been receiving targeted therapy (with omalizumab, benralizumab, mepolizumab, dupilumab, or tezepelumab) for at least 6 months, with no upper limit on the duration of treatment.
Able to understand the informed consent form and willing to consent to participate in a recorded semi-structured interview, as well as to the anonymized processing of their data.
You may not be if
Any person
Who refuses to participate in the research.
Who is unable to travel to participate in an in-person interview.
Who is under legal guardianship or conservatorship.
Who does not speak French.
Who has asthma associated with a systemic disease (GEPA, ABPA, etc.).
Clareo Health | Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies
